FDA reprimands two OTC drugmakers for inadequate screening for contaminants
Regulatory NewsJoanne S. Eglovitch
APIsAudit/inspectionChemistry, Manufacturing and Controls (CMC)ComplianceNorth AmericaOTCPharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/Policy